A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Linda Duska, Carolyn Krasner, David M. O’Malley, John L. Hays, Susan C. Modesitt, Cara Mathews, Kathleen N. Moore, Premal H. Thaker, Austin Miller, C. Purdy, William C. Zamboni, Andrew T. Lucas, Jeffrey G. Supko, Russell J. Schilder
Topics & Concepts
MedicineFallopian tube cancerBevacizumabOvarian cancerInternal medicineGastroenterologyPaclitaxelAdverse effectPharmacokineticsGynecologic oncologyAnemiaResponse Evaluation Criteria in Solid TumorsCamptothecinOncologyFallopian tubePhases of clinical researchIrinotecanCancerSurgeryChemotherapyColorectal cancerOrganic chemistryChemistryIntraperitoneal and Appendiceal MalignanciesCancer therapeutics and mechanismsOvarian cancer diagnosis and treatment